Toenail selenium, plasma selenoprotein P and risk of advanced prostate cancer: A nested case‐control study. Issue 4 (4th September 2020)

• Record Type: Journal Article
• Authors: Outzen, Malene; Tjønneland, Anne; Hughes, David J.; Jenab, Mazda; Frederiksen, Kirsten; Schomburg, Lutz; Morris, Steve; Overvad, Kim; Olsen, Anja
• Is Part Of: International journal of cancer. Volume 148:Issue 4(2021)
• Page Start: 876
• Page End: 883
• Publication Date: 2020-09-04
• Subjects: biomarkers -- nested case‐control study -- prostate cancer -- selenium -- single nucleotide polymorphisms; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.33267
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract: Low selenium status may be associated with increased risk of prostate cancer (PC), particularly aggressive PC, and variation in selenoprotein genes may constitute an important modifying factor. We aimed to investigate the association between two selenium status biomarkers [toenail selenium, plasma selenoprotein P (SELENOP)] and risk of advanced, high‐grade and advanced‐stage PC. We further studied whether variations in selenoprotein genes were associated with PC risk and selenium biomarker concentrations. In the "Diet, Cancer and Health" cohort, 27 178 men aged 50 to 65 years were enrolled from 1993 to 1997. Between baseline and 2012, 1160 cohort participants were diagnosed with advanced PC; among these 462 had high‐grade and 281 had advanced‐stage disease at diagnosis. Each case was risk set‐matched to one control. Toenail selenium and plasma SELENOP concentrations were measured by neutron activation analysis and a SELENOP‐ELISA, respectively, and genotyping was performed for 27 selected single nucleotide polymorphisms (SNPs) in 12 selenium pathway genes (including seven selenoproteins) by allele‐specific PCR. Toenail selenium and circulating SELENOP concentrations were not associated with advanced, high‐grade or advanced‐stage PC. After adjustment for multiple testing, none of the genes were associated with PC risk. Neither toenail selenium nor plasma SELENOP was associated with advanced, high‐grade or advanced‐stage PC. Abstract : What's new? Whether selenium has a preventive role in prostate cancer remains unclear. In particular, few studies have investigated the selenium‐prostate cancer risk association in low selenium status cohorts. In this study involving a Danish cohort, no association was found between toenail selenium or plasma selenoprotein P levels and risk of advanced, high‐grade, or advanced‐stage prostate cancer. In addition, no associations were identified between single nucleotide polymorphisms in selenium pathway genes and prostate cancer risk. The results indicate that selenium status has no impact on prostate cancer prevention.